**Name of Journal: *World Journal of Nephrology***

**ESPS Manuscript NO: 21958**

**Manuscript Type: Review**

**Adult stem cells as a tool for kidney regeneration**

Suzuki E *et al.* Adult stem cells for kidney regeneration

**Etsu Suzuki, Daishi Fujita, Masao Takahashi, Shigeyoshi Oba, Hiroaki Nishimatsu**

**Etsu Suzuki**, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki 216-8512, Japan

**Daishi Fujita, Masao Takahashi, Shigeyoshi Oba,** The Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo 113-8655, Japan

**Hiroaki Nishimatsu,** the Department of Urology, Faculty of Medicine, University of Tokyo, Tokyo 113-8655, Japan

**Author contributions:** Suzuki E, Fujita D, Takahashi M, Oba S, and Nishimatsu H contributed to this paper.

**Conflict-of-interest** **statement:** The authors declare no conflicts of interest regarding this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Etsu Suzuki, MD, PhD,** Institute of Medical Science, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8512, Japan. esuzuki-tky@umin.ac.jp

**Telephone:** +81-44-9778361

**Received:** August 10, 2015

**Peer-review started:** August 11, 2015

**First decision:** September 21, 2015

**Revised:** September 27, 2015

**Accepted:** November 23, 2015

**Article in press:**

**Published online:**

**Abstract**

Kidney regeneration is a challenging but promising strategy aimed at reducing the progression to end-stage renal disease (ESRD) and improving the quality of life of patients with ESRD. Adult stem cells are multipotent stem cells that reside in various tissues, such as bone marrow and adipose tissue. Although intensive studies to isolate kidney stem/progenitor cells from the adult kidney have been performed, it remains controversial whether stem/progenitor cells actually exist in the mammalian adult kidney. The efficacy of mesenchymal stem cells (MSCs) in the recovery of kidney function has been demonstrated in animal nephropathy models, such as acute tubular injury, glomerulonephritis, renal artery stenosis, and remnant kidney. However, their beneficial effects seem to be mediated largely *via* their paracrine effects rather than their direct differentiation into renal parenchymal cells. MSCs not only secrete bioactive molecules directly into the circulation, but they also release various molecules, such as proteins, mRNA, and microRNA, in membrane-covered vesicles. A detailed analysis of these molecules and an exploration of the optimal combination of these molecules will enable the treatment of patients with kidney disease without using stem cells. Another option for the treatment of patients with kidney disease using adult somatic cells is a direct/indirect reprogramming of adult somatic cells into kidney stem/progenitor cells. Although many hurdles still need to be overcome, this strategy will enable bona fide kidney regeneration rather than kidney repair using remnant renal parenchymal cells.

**Key words:** Adult stem cells; Mesenchymal stem cells; Paracrine factors; Extracellular vesicles; Direct reprogramming; Indirect reprogramming

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Although intensive studies have been performed to isolate kidney stem/progenitor cells from the mammalian adult kidney, whether stem/progenitor cells actually exist in the adult kidney is still debated. Mesenchymal stem cells seem to exert beneficial effects *via* paracrine effects rather than by direct differentiation into renal parenchymal cells. In this review, we also introduce potential roles of extracellular vesicles released from stem cells and direct/indirect reprogramming of adult somatic cells by which kidney stem/progenitor cells will be formed in the future.

Suzuki E, Fujita D, Takahashi M, Oba S, and Nishimatsu H. Adult stem cells as a tool for kidney regeneration. *World J Nephrol* 2015; In press

**INTRODUCTION**

The kidney is a vital organ that plays various roles, such as the excretion of waste products; regulation of systemic fluid volume, electrolytes, and pH; maintenance of systemic blood pressure; and erythropoietin production. These functions are performed by the nephrons, the functional units of the kidney. If the structure and/or function of the nephrons are damaged because of diseases, such as diabetes, hypertension, and glomerulonephritis, and if such damages continue to progress, renal function gradually deteriorates. The kidney finally becomes unable to perform its critical roles, resulting in renal failure.

There are two therapeutic options for the treatment of end-stage renal disease (ESRD). One is dialysis therapy, which compromises patients’ quality of life and cannot substitute for all kidney functions. Another is renal transplantation, which is limited because of the lack of sufficient donors. To explore a better treatment for ESRD, it is necessary to find strategies to regenerate the kidney. In this respect, stem cell therapy for the kidney has been intensively studied recently.

Stem cells are defined as cells that are capable of self-renewal and can differentiate into a variety of phenotypes[[1](#_ENREF_1)]. Adult stem cells (ASCs) are multipotent stem cells that reside in various tissues, such as the bone marrow, adipose tissue, and skeletal muscle[[2](#_ENREF_2),[3](#_ENREF_3)]. In this article, we review the possibility of kidney regeneration using ASCs.

***Stem cells in the embryonic kidney***

Although stem/progenitor cells in the embryonic kidney are beyond the scope of this review, we briefly describe the process of kidney organogenesis, because genetic programs that are activated during kidney organogenesis are reactivated in disease states, such as acute tubular injuries. Kidney organogenesis initiates with the interaction of the ureteric bud (UB) derived from the Wolffian duct with the metanephric mesenchyme (MM). A proportion of the MM is located adjacent to the UB, called the cap mesenchyme (CM). The CM then aggregates at the tip of the UB and differentiates into all epithelial cells of nephrons, except the collecting tubules. It is now well established that the CM contains stem/progenitor cells for kidney organogenesis[[4](#_ENREF_4)]. The CM expresses unique transcription factors, such as *Pax*2, *Six*2, and *Sall*1[[5](#_ENREF_5)]. Although stem cells in the embryonic kidney are a promising source for kidney regeneration, their clinical use is strictly limited mainly because of the ethical concerns and small number of stem cells. Therefore, the search for stem/progenitor cells in the adult kidney has been intensively performed.

***Stem/progenitor cells in the adult kidney***

Four different methods have been used in an attempt to isolate stem/progenitor cells from the adult kidney (Table 1).

**Label-retaining cells (LRCs):** To conserve the proliferation capacity for a lifetime and to prevent genetic injuries during mitosis, stem cells cycle very slowly. Stem/progenitor cells in the kidney were isolated using this property. Cells were pulse-labeled with a dye, such as 5-bromo-2-deoxyuridine. Then, slow-cycling LRCs were detected following a chase period. Maeshima *et al*[[6](#_ENREF_6)] detected LRCs predominantly in the renal tubular cells of the adult rat kidney. LRCs proliferated in response to ischemia/reperfusion injury and contributed to the repair of renal tubules. In another study, Maeshima *et al*[[7](#_ENREF_7)] also demonstrated that LRCs were integrated into epithelial components of the nephron when transplanted into the metanephric kidney, suggesting that LRCs were multipotent stem cells. Oliver *et al*[[8](#_ENREF_8)] detected LRCs in the kidney papilla of adult rats. LRCs proliferated after the induction of ischemia in the kidney and migrated toward the medulla. They also injected renal papillary cells into the subcapsular area of the kidney and found that some cells were incorporated into renal tubules.

**Side population cells:** Because stem cells extrude dyes, such as Rhodamine 123 and Hoechst 33342, *via* the ATP-binding cassette protein[[9](#_ENREF_9)], they are located in a unique position on the fluorescent-assisted cell sorting scattered plot and are called side population (SP) cells. Iwatani *et al*[[10](#_ENREF_10)] isolated SP cells from the adult rat kidney. However, the cells did not participate in the kidney repair following experimental glomerulonephritis or gentamicin-induced nephropathy. Hishikawa *et al*[[11](#_ENREF_11)] isolated SP cells from the adult murine kidney. These cells expressed musclin/MyoR and improved renal function when injected systemically into mice with the induction of acute tubular injury by cisplatin administration. Furthermore, SP cells expressed renoprotective factors, such as hepatocyte growth factor (HGF), vascular endothelial growth factor, and bone morphogenetic protein 7 in a cisplatin-induced acute kidney injury (AKI) model. Challen *et al*[[12](#_ENREF_12)] also isolated SP cells from the adult murine kidney. These cells were located predominantly in the proximal tubules and integrated into the MM- and UB-derived structures when injected into the embryonic kidney, suggesting that they were multipotent stem cells. However, these cells were barely incorporated into the renal tissues when administered to an adriamycin-induced kidney injury model, although renal function was recovered, probably because of their paracrine effect.

**Cell surface markers:** Cell surface markers, such as CD133, were used to isolate stem/progenitor cells from the adult kidney. Although CD133 is not a specific marker for kidney stem cells, it is a universal marker for stem cells in other tissues, such as hematopoietic stem cells, vascular endothelial progenitor cells (EPCs), and cancer stem cells[[13](#_ENREF_13),[14](#_ENREF_14)]. Bussolati *et al*[[15](#_ENREF_15)] isolated CD133+ cells from the adult human kidney. These cells expressed *Pax*2, but not CD34 or CD45, markers for hematopoietic stem cells. They could also be induced to differentiate into tubular epithelial cells and endothelial cells *in vitro*. When these cells were administered intravenously in a glycerol-induced AKI model of severe combined immune deficiency (SCID) mice, they were incorporated predominantly into the proximal and distal tubules. Sagrinati *et al*[[16](#_ENREF_16)] isolated CD133+ and CD24+ cells from human parietal epithelial cells in the Bowman’s capsule after culturing glomeruli. When cultured in appropriate conditions, these cells were differentiated into tubular epithelial cells, osteogenic cells, adipocytes, and neuronal cells. These cells were integrated predominantly into renal tubules when they were injected intravenously in SCID mice that were treated with glycerol to induce acute tubular injuries. Dekel *et al*[[17](#_ENREF_17)] isolated stem cell antigen-1 (Sca1)-positive cells from the adult mouse kidney. The Sca1+ cells were located mainly in the papilla. When these cells were administered to an ischemia-induced AKI model, some of these cells were integrated into renal tubules.

**Cell culture:** A unique cell population was isolated during the culture of dispersed cells derived from the adult kidney. Gupta *et al*[[18](#_ENREF_18)] isolated progenitor-like cells from the adult rat kidney that express vimentin, CD90, *Pax*2, and *Oct*4, a marker for embryonic stem cells. These cells were incorporated into renal tubules when injected under the capsule of the kidney or intra-arterially, following ischemia-reperfusion injury of the kidney.

***Arguments against the presence of stem/progenitor cells in the mammalian adult kidney***

Although aforementioned results suggest that renal stem/progenitor cells exist in the adult kidney, some reports demonstrated that differentiated renal tubular cells, but not renal stem/progenitor cells, can completely regenerate renal tubules after injury. Humphreys *et al*[[19](#_ENREF_19)] used genetic fate-mapping techniques in which renal epithelial cells derived from the CM (from the Bowman’s capsule to the junction of the connecting segment and collecting duct) were labeled with either -galactosidase or red fluorescent protein (RFP). After ischemia-reperfusion injury, approximately 50% of the proximal tubular cells coexpressed both RFP and Ki67, a cell proliferation marker that is expressed during the S-M phases of the cell cycle. These findings suggested that intrinsic renal tubular cells proliferate in response to injury. Furthermore, approximately 95% of tubular epithelial cells expressed RFP prior to injury, after one cycle of injury, and after two cycles of injury, indicating that no dilution of the RFP+ tubular epithelial cells occurred. These results suggested that differentiated renal epithelial cells proliferate well in response to the injury and that stem and/or progenitor cells residing in the interstitium did not participate in the regeneration of the tubules. Kusaba *et al*[[20](#_ENREF_20)] used a genetically modified mouse in which the tdTomato protein, which fluoresces in a red color, expressed only in differentiated proximal renal tubules. No dilution of tdTomato+ cells was observed after ischemia-reperfusion injury, suggesting that stem/progenitor cells in renal tubules did not participate in the regeneration of renal tubules. Furthermore, they observed that tdTomate+ proximal tubules expressed CD24 and CD133, markers for stem/progenitor cells. These findings suggested that renal tubules were dedifferentiated and expressed stem cell markers during their proliferation and participation in the repair of renal tubules. These results did not support that stem/progenitor cells in renal tubules and in the interstitium participated in the regeneration of renal tubular cells in acute tubular injury. Nonetheless, a potential role of intrinsic stem/progenitor cells in kidney regeneration is not completely excluded from these results, because stem/progenitor cells may participate in the repair of other cell types, such as podocytes[[21](#_ENREF_21)]. It is difficult to distinguish renal stem/progenitor cells from dedifferentiated renal epithelial cells. Identification of specific markers that are exclusively expressed in stem/progenitor cells, but not in dedifferentiated renal epithelial cells, will be required to resolve this issue.

***Mesenchymal stem cells***

The MSCs reside in various organs, such as bone marrow, subcutaneous adipose tissue, and skeletal muscles. Bone marrow mesenchymal stem cells (BMMSCs) and adipose tissue-derived MSCs (ADSCs) are particularly interesting, because a large amount of MSCs can be collected with relatively less invasive procedures.

**BMMSCs:** Many studies have demonstrated the efficacy of BMMSCs in the treatment of kidney disease using animal models of AKI[[22-26](#_ENREF_22)], podocyte injury[[27](#_ENREF_27)], glomerulonephropathy[[28-30](#_ENREF_28)], a remnant kidney[[31](#_ENREF_31)], and kidney transplantation[[32](#_ENREF_32)] (Table 2). Although early studies indicated BMMSCs could be differentiated into renal epithelial cells[[22](#_ENREF_22),[23](#_ENREF_23)] and mesangial cells[[30](#_ENREF_30)], recent evidence suggests that the differentiation capacity of BMMSCs is limited. Thus, BMMSCs do not appear to differentiate into renal parenchymal cells *in vivo[*[*33*](#_ENREF_33)*]*. The beneficial effects of BMMSCs on renal function seem to be largely mediated by paracrine factors produced by BMMSCs that have anti-apoptotic, proangiogenic, and/or immune modulatory effects[[34-36](#_ENREF_34)]. The transdifferentiation of BMMSCs observed in early reports may reflect cell fusion. If BMMSCs fuse with resident cells in the kidney, they acquire a phenotype of resident cells. Thus, it appears as if BMMSCs were differentiated into resident cells. Indeed, several reports have demonstrated that BMMSCs are capable of fusing with other cell types[[37](#_ENREF_37),[38](#_ENREF_38)]. A phase I clinical study evaluated the safety and efficacy of allogenic BMMSC administration for the prevention of AKI after open-heart surgery[[39](#_ENREF_39)]. This study enrolled 16 patients who required on-pump cardiac surgery and who were at a high risk of postoperative AKI due to underlying chronic kidney disease, advanced age, diabetes mellitus, and congestive heart failure. Allogenic BMMSCs were injected into the suprarenal aorta after surgery. The primary objective was the safety of BMMSC administration. The secondary objective was the efficacy of this treatment compared with well-matched historical controls. This treatment appeared to be both safe and effective as no adverse events related to the procedure were reported, and renal function was well preserved post-operatively, with no patients requiring hemodialysis after surgery, whereas 20% of the controls developed AKI. This is the only clinical trial published so far in which ASCs were used to treat kidney disease.

**ADSCs:** ADSCs are another type of MSCs residing in subcutaneous adipose tissues. Because the subcutaneous adipose tissues are abundant and can be easily harvested using liposuction, ADSCs are promising stem cells for clinical use. The efficacy of ADSC administration in the treatment of kidney disease has been demonstrated in animal models of AKI[[40-42](#_ENREF_40)], glomerulonephropathy[[43](#_ENREF_43)], renal artery stenosis[[44-46](#_ENREF_44)], and progressive renal fibrosis[[47](#_ENREF_47)] (Table 3). ADSCs also seem to recover renal function largely *via* paracrine effects[[41](#_ENREF_41),[42](#_ENREF_42)].

**EPCs:** EPCs were originally isolated from human peripheral blood using CD34 as a marker for positive selection[[48](#_ENREF_48)]. The CD34+ mononuclear blood cells obtained the characteristics of vascular endothelial cells (VECs) when cultured on fibronectin-coated dishes. EPCs were reportedly incorporated in ischemic tissues *in vivo* and expressed markers for VECs such as CD31 when introduced into the circulation using a hindlimb ischemia model. The efficacy of EPC administration in the recovery of renal function was reported in animal models of AKI[[49](#_ENREF_49)] and renal artery stenosis[[50](#_ENREF_50),[51](#_ENREF_51)]. Interestingly, the function of EPCs was deteriorated in chronic kidney disease (CKD) patients[[52](#_ENREF_52)], suggesting that the autologous transplantation of EPCs may not be suitable for the treatment of CKD.

***Umbilical cord blood-derived MSCs***

Umbilical cord blood (UCB) contains MSCs, and the efficacy of UCB administration in the restoration of renal function has been reported in animal AKI models[[53](#_ENREF_53),[54](#_ENREF_54)]. Morigi *et al*[[53](#_ENREF_53)] injected human UCB-derived MSCs to immunodeficient mice with cisplatin-induced acute tubular injury. They demonstrated that these cells ameliorated tubular injury, resulting in the recovery of renal function. They also cocultured UCB-derived MSCs with cisplatin-treated proximal tubular cells (HK-2 cells) and demonstrated that the expression of HGF was particularly induced and that of interleukin 1- and tumor necrosis factor- (TNF- was significantly decreased in the coculture system. These findings suggested that the modulation of paracrine factors in the kidney was implicated in the UCB-induced recovery of renal function. Panepucci *et al*[[55](#_ENREF_55)]. compared the gene expression profile of UCB-derived MSCs and BMMSCs Although both MSCs expressed similar sets of genes, BMMSCs predominantly expressed a set of genes related to antimicrobial activity and osteogenesis, whereas UCB-derived MSCs predominantly expressed genes related to matrix remodeling and angiogenesis, suggesting that UBC-derived MSCs and BMMSCs may have distinct activities *in vivo*.

***Amniotic fluid stem cells***

Human amniotic fluid contains stem cells derived from embryos, and thus, is a promising source of stem cells. The efficacy of human amniotic fluid stem cells (HAFSCs) has been demonstrated in animal models of AKI[[56](#_ENREF_56),[57](#_ENREF_57)]. Houser *et al*[[56](#_ENREF_56)] compared the characteristics of HAFSCs with that of BMMSCs. They found that compared with BMMSCs, HAFSCs had a more potent anti-apoptotic activity against renal tubular cells but lesser stimulatory activity for the proliferation of renal tubular cells. They also demonstrated that HAFSCs and BMMSCs expressed distinct sets of paracrine factors, suggesting that HAFSCs and BMMSCs may have distinct activities *in vivo*.

***Direct/indirect reprogramming of adult somatic cells***

Another strategy for kidney regeneration is to create pluripotent stem cells and progenitor cells, whose destination is limited to one or several cell lineages, or terminally differentiated renal parenchymal cells from adult somatic cells *via* direct/indirect reprogramming. Indirect reprogramming is a strategy in which adult somatic cells are induced to dedifferentiate into pluripotent stem cells and re-differentiate into specific cell types. Direct reprogramming involves a strategy in which adult somatic cells are induced to differentiate directly into another cell type. Since the discovery of induced pluripotent stem (iPS) cells[[58](#_ENREF_58),[59](#_ENREF_59)], it is not difficult to prepare iPS cells from various adult somatic cells. Indeed, several reports have demonstrated a successful preparation of nephrogenic intermediate mesoderm, from which the MM and the UB derive, using iPS cells[[60-62](#_ENREF_60)]. However, several hurdles remain to be overcome before iPS cells can be used practically to regenerate the kidney. First, the efficiency of iPS cell preparation from adult somatic cells is still low. Second, it is still challenging to prepare kidney stem/progenitor cells that exist in the CM from iPS cells. Third, even if kidney stem/progenitor cells are successfully created from iPS cells, it is difficult to continue to culture and expand those stem/progenitor cells while maintaining their unique properties. The reason for this limitation is that the niche for kidney stem/progenitor cells has not been clearly understood. Therefore, further studies will be required to use indirect reprogramming for kidney regeneration. Recently, several reports have demonstrated that a direct reprogramming method was useful for kidney regeneration. Hendry *et al*[[63](#_ENREF_63)] introduced 6 transcription factors into a human adult renal proximal tubular cell line. These cells were localized in *Six2*+ and Wilm’s tumor 1+ compartment in an *ex vivo* organoid culture assay. These findings suggest that these cells obtained properties similar to kidney stem/progenitor cells. Papadimou *et al*[[64](#_ENREF_64)] incubated permeabilized human BMMSCs with the extracts of human proximal tubular epithelial cells and obtained a cell population similar to proximal renal tubular cells. These cells were integrated in tubular structures in an *ex vivo* organoid culture assay. Furthermore, these cells were engrafted in renal tubules when administered to a cisplatin-induced AKI model. Therefore, direct reprogramming seems to be a promising strategy for kidney regeneration. It has been reported that iPS cells derived from various cell types are not identical in their differentiation capacity[[65-67](#_ENREF_65)], probably because iPS cells maintain epigenetic memory of their parental cells. Thus, it may be better to use renal parenchymal cells for reprogramming than cells derived from tissues other than the kidney.

***Possible roles of extracellular vesicles released from MSCs***

MSCs not only secrete bioactive molecules directly into the circulation but also release extracellular vesicles (EVs)[[68](#_ENREF_68)], such as exosomes that contain proteins, mRNA, and microRNA[[69](#_ENREF_69),[70](#_ENREF_70)]. Several reports have demonstrated that EV administration restored the kidney function in animal models of AKI[[26](#_ENREF_26),[71-73](#_ENREF_71)]. Bruno *et al*[[71](#_ENREF_71)] isolated EVs from supernatants of human BMMSCs and examined their effects on the proliferation and apoptosis in renal epithelial cells. EVs were incorporated in renal epithelial cells *in vitro* and the incorporation depended on CD44 and 1-interin. EVs stimulated the proliferation and inhibited apoptosis of renal epithelial cells. These effects were diminished when EVs were treated with RNase prior to administration. Furthermore, the authors administered EVs to immunodeficient mice with glycerol-induced acute tubular injury and demonstrated that EV administration restored renal function. Moreover, these beneficial effects were diminished when EVs were pretreated with RNase. Tomasoni *et al*[[74](#_ENREF_74)] isolated EVs from supernatants of human BMMSCs and demonstrated that EVs contained mRNA for the insulin-like growth factor-1 receptor (IGF1R). When cisplatin-treated renal epithelial cells were incubated with EVs, proliferative capacity of renal epithelial cells increased significantly; however, the stimulatory effect was diminished when the expression of IGF1R mRNA in BMMSCs was suppressed using small interfering RNA to IGF1R prior to EV harvest. Zhou *et al*[[75](#_ENREF_75)] administered EVs harvested from human UCB-derived MSCs to a rat model of cisplatin-induced AKI. EV administration significantly restored renal function and morphology. Therefore, EVs seem to contain various bioactive molecules that can be used for the treatment of kidney injury.

**FUTURE DIRECTIONS**

It seems that there are two major directions to improve the quality of stem cell therapy for kidney diseases. One is to analyze bioactive molecules released from stem cells in more details. If an ideal combination of bioactive proteins, mRNA, and/or microRNA is elucidated, stem cells *per se* will not be necessary in the future. Although BMMSCs have been used in the clinical setting to treat patients with cardiovascular disease[[76-80](#_ENREF_76)], concern about tumorigenesis still remains[[81](#_ENREF_81)]. Furthermore, BMMSCs isolated under uremic conditions have less capacity for the proliferation, survival, and secretion of paracrine factors compared with those isolated from normal controls[[82-84](#_ENREF_82)]. Patients who need stem cell therapy are probably not a suitable source of high-quality stem cells, indicating that autologous stem cell transplantation may not be effective in these patients. Therefore, cell-free therapy seems attractive. Another alternative is to explore strategies to directly and/or indirectly reprogram adult somatic cells into kidney stem/progenitor cells. If efficient and safe methods to induce direct/indirect reprogramming are explored, *bona fide* kidney regeneration rather than kidney repair using remnant renal parenchymal cells will be possible in the future.

**CONCLUSION**

Although intensive studies have been performed to isolate kidney stem/progenitor cells from the adult kidney, it is debated whether kidney stem/progenitor cells actually exist in the adult kidney. There are no specific markers and/or assays to discriminate kidney stem/progenitor cells from dedifferentiated renal epithelial cells. MSCs are effective to repair the kidney in various animal models; however, their beneficial effects can be largely attributed to paracrine factors that are secreted from MSCs. In addition, MSCs release EVs that contain mRNA and microRNA as well as proteins. These EV-derived molecules may also play beneficial roles in the repair of the kidney. It will be necessary to elucidate ideal combinations of the molecules released from MSCs to establish a strategy for the maximal stimulation of kidney repair without using stem cells. It will also be necessary to explore strategies to directly and/or indirectly reprogram somatic cells to kidney stem/progenitor cells to regenerate the kidney.

**REFERENCES**

1 **Morrison SJ**, Shah NM, Anderson DJ. Regulatory mechanisms in stem cell biology. *Cell* 1997; **88**: 287-298 [PMID: 9039255]

2 **Jiang Y**, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. *Exp Hematol* 2002; **30**: 896-904 [PMID: 12160841]

3 **Schäffler A**, Büchler C. Concise review: adipose tissue-derived stromal cells--basic and clinical implications for novel cell-based therapies. *Stem Cells* 2007; **25**: 818-827 [PMID: 17420225 DOI: 10.1634/stemcells.2006-0589]

4 **Kobayashi A**, Valerius MT, Mugford JW, Carroll TJ, Self M, Oliver G, McMahon AP. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. *Cell Stem Cell* 2008; **3**: 169-181 [PMID: 18682239 DOI: 10.1016/j.stem.2008.05.020]

5 **Reidy KJ**, Rosenblum ND. Cell and molecular biology of kidney development. *Semin Nephrol* 2009; **29**: 321-337 [PMID: 19615554 DOI: 10.1016/j.semnephrol.2009.03.009]

6 **Maeshima A**, Yamashita S, Nojima Y. Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. *J Am Soc Nephrol* 2003; **14**: 3138-3146 [PMID: 14638912]

7 **Maeshima A**, Sakurai H, Nigam SK. Adult kidney tubular cell population showing phenotypic plasticity, tubulogenic capacity, and integration capability into developing kidney. *J Am Soc Nephrol* 2006; **17**: 188-198 [PMID: 16338966 DOI: 10.1681/ASN.2005040370]

8 **Oliver JA**, Maarouf O, Cheema FH, Martens TP, Al-Awqati Q. The renal papilla is a niche for adult kidney stem cells. *J Clin Invest* 2004; **114**: 795-804 [PMID: 15372103 DOI: 10.1172/JCI20921]

9 **Zhou S**, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med* 2001; **7**: 1028-1034 [PMID: 11533706 DOI: 10.1038/nm0901-1028]

10 **Iwatani H**, Ito T, Imai E, Matsuzaki Y, Suzuki A, Yamato M, Okabe M, Hori M. Hematopoietic and nonhematopoietic potentials of Hoechst(low)/side population cells isolated from adult rat kidney. *Kidney Int* 2004; **65**: 1604-1614 [PMID: 15086898 DOI: 10.1111/j.1523-1755.2004.00561.x]

11 **Hishikawa K**, Marumo T, Miura S, Nakanishi A, Matsuzaki Y, Shibata K, Ichiyanagi T, Kohike H, Komori T, Takahashi I, Takase O, Imai N, Yoshikawa M, Inowa T, Hayashi M, Nakaki T, Nakauchi H, Okano H, Fujita T. Musculin/MyoR is expressed in kidney side population cells and can regulate their function. *J Cell Biol* 2005; **169**: 921-928 [PMID: 15967813 DOI: 10.1083/jcb.200412167]

12 **Challen GA**, Bertoncello I, Deane JA, Ricardo SD, Little MH. Kidney side population reveals multilineage potential and renal functional capacity but also cellular heterogeneity. *J Am Soc Nephrol* 2006; **17**: 1896-1912 [PMID: 16707564 DOI: 10.1681/ASN.2005111228]

13 **Hristov M**, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. *Arterioscler Thromb Vasc Biol* 2003; **23**: 1185-1189 [PMID: 12714439 DOI: 10.1161/01.ATV.0000073832.49290.B5]

14 **Bidlingmaier S**, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. *J Mol Med (Berl)* 2008; **86**: 1025-1032 [PMID: 18535813 DOI: 10.1007/s00109-008-0357-8]

15 **Bussolati B**, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, Camussi G. Isolation of renal progenitor cells from adult human kidney. *Am J Pathol* 2005; **166**: 545-555 [PMID: 15681837 DOI: 10.1016/S0002-9440(10)62276-6]

16 **Sagrinati C**, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C, Gacci M, Squecco R, Carini M, Gesualdo L, Francini F, Maggi E, Annunziato F, Lasagni L, Serio M, Romagnani S, Romagnani P. Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. *J Am Soc Nephrol* 2006; **17**: 2443-2456 [PMID: 16885410 DOI: 10.1681/ASN.2006010089]

17 **Dekel B**, Zangi L, Shezen E, Reich-Zeliger S, Eventov-Friedman S, Katchman H, Jacob-Hirsch J, Amariglio N, Rechavi G, Margalit R, Reisner Y. Isolation and characterization of nontubular sca-1+lin- multipotent stem/progenitor cells from adult mouse kidney. *J Am Soc Nephrol* 2006; **17**: 3300-3314 [PMID: 17093069 DOI: 10.1681/ASN.2005020195]

18 **Gupta S**, Verfaillie C, Chmielewski D, Kren S, Eidman K, Connaire J, Heremans Y, Lund T, Blackstad M, Jiang Y, Luttun A, Rosenberg ME. Isolation and characterization of kidney-derived stem cells. *J Am Soc Nephrol* 2006; **17**: 3028-3040 [PMID: 16988061 DOI: 10.1681/ASN.2006030275]

19 **Humphreys BD**, Valerius MT, Kobayashi A, Mugford JW, Soeung S, Duffield JS, McMahon AP, Bonventre JV. Intrinsic epithelial cells repair the kidney after injury. *Cell Stem Cell* 2008; **2**: 284-291 [PMID: 18371453 DOI: 10.1016/j.stem.2008.01.014]

20 **Kusaba T**, Lalli M, Kramann R, Kobayashi A, Humphreys BD. Differentiated kidney epithelial cells repair injured proximal tubule. *Proc Natl Acad Sci USA* 2014; **111**: 1527-1532 [PMID: 24127583 DOI: 10.1073/pnas.1310653110]

21 **Ronconi E**, Sagrinati C, Angelotti ML, Lazzeri E, Mazzinghi B, Ballerini L, Parente E, Becherucci F, Gacci M, Carini M, Maggi E, Serio M, Vannelli GB, Lasagni L, Romagnani S, Romagnani P. Regeneration of glomerular podocytes by human renal progenitors. *J Am Soc Nephrol* 2009; **20**: 322-332 [PMID: 19092120 DOI: 10.1681/ASN.2008070709]

22 **Herrera MB**, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. *Int J Mol Med* 2004; **14**: 1035-1041 [PMID: 15547670]

23 **Morigi M**, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, Rottoli D, Angioletti S, Benigni A, Perico N, Alison M, Remuzzi G. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. *J Am Soc Nephrol* 2004; **15**: 1794-1804 [PMID: 15213267]

24 **Lange C**, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR, Westenfelder C. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. *Kidney Int* 2005; **68**: 1613-1617 [PMID: 16164638 DOI: 10.1111/j.1523-1755.2005.00573.x]

25 **Morigi M**, Introna M, Imberti B, Corna D, Abbate M, Rota C, Rottoli D, Benigni A, Perico N, Zoja C, Rambaldi A, Remuzzi A, Remuzzi G. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. *Stem Cells* 2008; **26**: 2075-2082 [PMID: 18499895 DOI: 10.1634/stemcells.2007-0795]

26 **Reis LA**, Borges FT, Simões MJ, Borges AA, Sinigaglia-Coimbra R, Schor N. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. *PLoS One* 2012; **7**: e44092 [PMID: 22970165 DOI: 10.1371/journal.pone.0044092]

27 **Zoja C**, Garcia PB, Rota C, Conti S, Gagliardini E, Corna D, Zanchi C, Bigini P, Benigni A, Remuzzi G, Morigi M. Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. *Am J Physiol Renal Physiol* 2012; **303**: F1370-F1381 [PMID: 22952284 DOI: 10.1152/ajprenal.00057.2012]

28 **Kunter U**, Rong S, Djuric Z, Boor P, Müller-Newen G, Yu D, Floege J. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. *J Am Soc Nephrol* 2006; **17**: 2202-2212 [PMID: 16790513 DOI: 10.1681/ASN.2005080815]

29 **Ninichuk V**, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, Huss R, Akis N, Schlöndorff D, Anders HJ. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. *Kidney Int* 2006; **70**: 121-129 [PMID: 16723981 DOI: 10.1038/sj.ki.5001521]

30 **Wong CY**, Cheong SK, Mok PL, Leong CF. Differentiation of human mesenchymal stem cells into mesangial cells in post-glomerular injury murine model. *Pathology* 2008; **40**: 52-57 [PMID: 18038316 DOI: 10.1080/00313020701716367]

31 **Semedo P**, Correa-Costa M, Antonio Cenedeze M, Maria Avancini Costa Malheiros D, Antonia dos Reis M, Shimizu MH, Seguro AC, Pacheco-Silva A, Saraiva Camara NO. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. *Stem Cells* 2009; **27**: 3063-3073 [PMID: 19750536 DOI: 10.1002/stem.214]

32 **Franquesa M**, Herrero E, Torras J, Ripoll E, Flaquer M, Gomà M, Lloberas N, Anegon I, Cruzado JM, Grinyó JM, Herrero-Fresneda I. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. *Stem Cells Dev* 2012; **21**: 3125-3135 [PMID: 22494435 DOI: 10.1089/scd.2012.0096]

33 **Duffield JS**, Park KM, Hsiao LL, Kelley VR, Scadden DT, Ichimura T, Bonventre JV. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. *J Clin Invest* 2005; **115**: 1743-1755 [PMID: 16007251 DOI: 10.1172/JCI22593]

34 **Tögel F**, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. *Am J Physiol Renal Physiol* 2005; **289**: F31-F42 [PMID: 15713913 DOI: 10.1152/ajprenal.00007.2005]

35 **Tögel F**, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. *Am J Physiol Renal Physiol* 2007; **292**: F1626-F1635 [PMID: 17213465 DOI: 10.1152/ajprenal.00339.2006]

36 **Imberti B**, Morigi M, Tomasoni S, Rota C, Corna D, Longaretti L, Rottoli D, Valsecchi F, Benigni A, Wang J, Abbate M, Zoja C, Remuzzi G. Insulin-like growth factor-1 sustains stem cell mediated renal repair. *J Am Soc Nephrol* 2007; **18**: 2921-2928 [PMID: 17942965 DOI: 10.1681/ASN.2006121318]

37 **Terada N**, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, Meyer EM, Morel L, Petersen BE, Scott EW. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. *Nature* 2002; **416**: 542-545 [PMID: 11932747 DOI: 10.1038/nature730]

38 **Alvarez-Dolado M**, Pardal R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, Lois C, Morrison SJ, Alvarez-Buylla A. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. *Nature* 2003; **425**: 968-973 [PMID: 14555960 DOI: 10.1038/nature02069]

39 **Tögel FE**, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. *Nat Rev Nephrol* 2010; **6**: 179-183 [PMID: 20186233 DOI: 10.1038/nrneph.2009.229]

40 **Chen YT**, Sun CK, Lin YC, Chang LT, Chen YL, Tsai TH, Chung SY, Chua S, Kao YH, Yen CH, Shao PL, Chang KC, Leu S, Yip HK. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. *J Transl Med* 2011; **9**: 51 [PMID: 21545725 DOI: 10.1186/1479-5876-9-51]

41 **Kim JH**, Park DJ, Yun JC, Jung MH, Yeo HD, Kim HJ, Kim DW, Yang JI, Lee GW, Jeong SH, Roh GS, Chang SH. Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats. *Am J Physiol Renal Physiol* 2012; **302**: F1141-F1150 [PMID: 22205231 DOI: 10.1152/ajprenal.00060.2011]

42 **Katsuno T**, Ozaki T, Saka Y, Furuhashi K, Kim H, Yasuda K, Yamamoto T, Sato W, Tsuboi N, Mizuno M, Ito Y, Imai E, Matsuo S, Maruyama S. Low serum cultured adipose tissue-derived stromal cells ameliorate acute kidney injury in rats. *Cell Transplant* 2013; **22**: 287-297 [PMID: 22963874 DOI: 10.3727/096368912X655019]

43 **Furuhashi K**, Tsuboi N, Shimizu A, Katsuno T, Kim H, Saka Y, Ozaki T, Sado Y, Imai E, Matsuo S, Maruyama S. Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages. *J Am Soc Nephrol* 2013; **24**: 587-603 [PMID: 23471196 DOI: 10.1681/ASN.2012030264]

44 **Eirin A**, Zhu XY, Krier JD, Tang H, Jordan KL, Grande JP, Lerman A, Textor SC, Lerman LO. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. *Stem Cells* 2012; **30**: 1030-1041 [PMID: 22290832 DOI: 10.1002/stem.1047]

45 **Zhu XY**, Urbieta-Caceres V, Krier JD, Textor SC, Lerman A, Lerman LO. Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms. *Stem Cells* 2013; **31**: 117-125 [PMID: 23097349 DOI: 10.1002/stem.1263]

46 **Ebrahimi B**, Eirin A, Li Z, Zhu XY, Zhang X, Lerman A, Textor SC, Lerman LO. Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis. *PLoS One* 2013; **8**: e67474 [PMID: 23844014 DOI: 10.1371/journal.pone.0067474]

47 **Donizetti-Oliveira C**, Semedo P, Burgos-Silva M, Cenedeze MA, Malheiros DM, Reis MA, Pacheco-Silva A, Câmara NO. Adipose tissue-derived stem cell treatment prevents renal disease progression. *Cell Transplant* 2012; **21**: 1727-1741 [PMID: 22305061 DOI: 10.3727/096368911X623925]

48 **Asahara T**, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997; **275**: 964-967 [PMID: 9020076]

49 **Patschan D**, Krupincza K, Patschan S, Zhang Z, Hamby C, Goligorsky MS. Dynamics of mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning. *Am J Physiol Renal Physiol* 2006; **291**: F176-F185 [PMID: 16478972 DOI: 10.1152/ajprenal.00454.2005]

50 **Chade AR**, Zhu X, Lavi R, Krier JD, Pislaru S, Simari RD, Napoli C, Lerman A, Lerman LO. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. *Circulation* 2009; **119**: 547-557 [PMID: 19153272 DOI: 10.1161/CIRCULATIONAHA.108.788653]

51 **Chade AR**, Zhu XY, Krier JD, Jordan KL, Textor SC, Grande JP, Lerman A, Lerman LO. Endothelial progenitor cells homing and renal repair in experimental renovascular disease. *Stem Cells* 2010; **28**: 1039-1047 [PMID: 20506499 DOI: 10.1002/stem.426]

52 **Jie KE**, Zaikova MA, Bergevoet MW, Westerweel PE, Rastmanesh M, Blankestijn PJ, Boer WH, Braam B, Verhaar MC. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. *Nephrol Dial Transplant* 2010; **25**: 1875-1882 [PMID: 20083473 DOI: 10.1093/ndt/gfp749]

53 **Morigi M**, Rota C, Montemurro T, Montelatici E, Lo Cicero V, Imberti B, Abbate M, Zoja C, Cassis P, Longaretti L, Rebulla P, Introna M, Capelli C, Benigni A, Remuzzi G, Lazzari L. Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. *Stem Cells* 2010; **28**: 513-522 [PMID: 20049901 DOI: 10.1002/stem.293]

54 **Shalaby RH**, Rashed LA, Ismaail AE, Madkour NK, Elwakeel SH. Hematopoietic stem cells derived from human umbilical cord ameliorate cisplatin-induced acute renal failure in rats. *Am J Stem Cells* 2014; **3**: 83-96 [PMID: 25232508]

55 **Panepucci RA**, Siufi JL, Silva WA, Proto-Siquiera R, Neder L, Orellana M, Rocha V, Covas DT, Zago MA. Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. *Stem Cells* 2004; **22**: 1263-1278 [PMID: 15579645 DOI: 10.1634/stemcells.2004-0024]

56 **Hauser PV**, De Fazio R, Bruno S, Sdei S, Grange C, Bussolati B, Benedetto C, Camussi G. Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. *Am J Pathol* 2010; **177**: 2011-2021 [PMID: 20724594 DOI: 10.2353/ajpath.2010.091245]

57 **Rota C**, Imberti B, Pozzobon M, Piccoli M, De Coppi P, Atala A, Gagliardini E, Xinaris C, Benedetti V, Fabricio AS, Squarcina E, Abbate M, Benigni A, Remuzzi G, Morigi M. Human amniotic fluid stem cell preconditioning improves their regenerative potential. *Stem Cells Dev* 2012; **21**: 1911-1923 [PMID: 22066606 DOI: 10.1089/scd.2011.0333]

58 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

59 **Takahashi K**, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861-872 [PMID: 18035408 DOI: 10.1016/j.cell.2007.11.019]

60 **Araoka T**, Mae S, Kurose Y, Uesugi M, Ohta A, Yamanaka S, Osafune K. Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods. *PLoS One* 2014; **9**: e84881 [PMID: 24454758 DOI: 10.1371/journal.pone.0084881]

61 **Lam AQ**, Freedman BS, Morizane R, Lerou PH, Valerius MT, Bonventre JV. Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers. *J Am Soc Nephrol* 2014; **25**: 1211-1225 [PMID: 24357672 DOI: 10.1681/ASN.2013080831]

62 **Mae S**, Shono A, Shiota F, Yasuno T, Kajiwara M, Gotoda-Nishimura N, Arai S, Sato-Otubo A, Toyoda T, Takahashi K, Nakayama N, Cowan CA, Aoi T, Ogawa S, McMahon AP, Yamanaka S, Osafune K. Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. *Nat Commun* 2013; **4**: 1367 [PMID: 23340407 DOI: 10.1038/ncomms2378]

63 **Hendry CE**, Vanslambrouck JM, Ineson J, Suhaimi N, Takasato M, Rae F, Little MH. Direct transcriptional reprogramming of adult cells to embryonic nephron progenitors. *J Am Soc Nephrol* 2013; **24**: 1424-1434 [PMID: 23766537 DOI: 10.1681/ASN.2012121143]

64 **Papadimou E**, Morigi M, Iatropoulos P, Xinaris C, Tomasoni S, Benedetti V, Longaretti L, Rota C, Todeschini M, Rizzo P, Introna M, Grazia de Simoni M, Remuzzi G, Goligorsky MS, Benigni A. Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts. *Stem Cell Reports* 2015; **4**: 685-698 [PMID: 25754206 DOI: 10.1016/j.stemcr.2015.02.002]

65 **Hu Q**, Friedrich AM, Johnson LV, Clegg DO. Memory in induced pluripotent stem cells: reprogrammed human retinal-pigmented epithelial cells show tendency for spontaneous redifferentiation. *Stem Cells* 2010; **28**: 1981-1991 [PMID: 20882530 DOI: 10.1002/stem.531]

66 **Polo JM**, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, Natesan S, Wagers AJ, Melnick A, Evans T, Hochedlinger K. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. *Nat Biotechnol* 2010; **28**: 848-855 [PMID: 20644536 DOI: 10.1038/nbt.1667]

67 **Quattrocelli M**, Palazzolo G, Floris G, Schöffski P, Anastasia L, Orlacchio A, Vandendriessche T, Chuah MK, Cossu G, Verfaillie C, Sampaolesi M. Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. *J Pathol* 2011; **223**: 593-603 [PMID: 21341275 DOI: 10.1002/path.2845]

68 **György B**, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, Pállinger E, Pap E, Kittel A, Nagy G, Falus A, Buzás EI. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. *Cell Mol Life Sci* 2011; **68**: 2667-2688 [PMID: 21560073 DOI: 10.1007/s00018-011-0689-3]

69 **Ambros V**. microRNAs: tiny regulators with great potential. *Cell* 2001; **107**: 823-826 [PMID: 11779458]

70 **Bartel DP**. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; **116**: 281-297 [PMID: 14744438]

71 **Bruno S**, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, Morando L, Busca A, Falda M, Bussolati B, Tetta C, Camussi G. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. *J Am Soc Nephrol* 2009; **20**: 1053-1067 [PMID: 19389847 DOI: 10.1681/ASN.2008070798]

72 **Gatti S**, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, Tetta C, Camussi G. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. *Nephrol Dial Transplant* 2011; **26**: 1474-1483 [PMID: 21324974 DOI: 10.1093/ndt/gfr015]

73 **Bruno S**, Grange C, Collino F, Deregibus MC, Cantaluppi V, Biancone L, Tetta C, Camussi G. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. *PLoS One* 2012; **7**: e33115 [PMID: 22431999 DOI: 10.1371/journal.pone.0033115]

74 **Tomasoni S**, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, Capelli C, Introna M, Remuzzi G, Benigni A. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. *Stem Cells Dev* 2013; **22**: 772-780 [PMID: 23082760 DOI: 10.1089/scd.2012.0266]

75 **Zhou Y**, Xu H, Xu W, Wang B, Wu H, Tao Y, Zhang B, Wang M, Mao F, Yan Y, Gao S, Gu H, Zhu W, Qian H. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. *Stem Cell Res Ther* 2013; **4**: 34 [PMID: 23618405 DOI: 10.1186/scrt194]

76 **Tateishi-Yuyama E**, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet* 2002; **360**: 427-435 [PMID: 12241713 DOI: 10.1016/S0140-6736(02)09670-8]

77 **Abdel-Latif A**, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. *Arch Intern Med* 2007; **167**: 989-997 [PMID: 17533201 DOI: 10.1001/archinte.167.10.989]

78 **Assmus B**, Rolf A, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Tillmanns H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Tonn T, Dimmeler S, Dill T, Zeiher AM, Schächinger V. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. *Circ Heart Fail* 2010; **3**: 89-96 [PMID: 19996415 DOI: 10.1161/CIRCHEARTFAILURE.108.843243]

79 **Leistner DM**, Fischer-Rasokat U, Honold J, Seeger FH, Schächinger V, Lehmann R, Martin H, Burck I, Urbich C, Dimmeler S, Zeiher AM, Assmus B. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. *Clin Res Cardiol* 2011; **100**: 925-934 [PMID: 21633921 DOI: 10.1007/s00392-011-0327-y]

80 **Walter DH**, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schlüter M, Tonn T, Seeger F, Dimmeler S, Lindhoff-Last E, Zeiher AM. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). *Circ Cardiovasc Interv* 2011; **4**: 26-37 [PMID: 21205939 DOI: 10.1161/CIRCINTERVENTIONS.110.958348]

81 **Jeong JO**, Han JW, Kim JM, Cho HJ, Park C, Lee N, Kim DW, Yoon YS. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. *Circ Res* 2011; **108**: 1340-1347 [PMID: 21493893 DOI: 10.1161/CIRCRESAHA.110.239848]

82 **Noh H**, Yu MR, Kim HJ, Jeon JS, Kwon SH, Jin SY, Lee J, Jang J, Park JO, Ziyadeh F, Han DC, Lee HB. Uremia induces functional incompetence of bone marrow-derived stromal cells. *Nephrol Dial Transplant* 2012; **27**: 218-225 [PMID: 21622994 DOI: 10.1093/ndt/gfr267]

83 **Idziak M**, Pędzisz P, Burdzińska A, Gala K, Pączek L. Uremic toxins impair human bone marrow-derived mesenchymal stem cells functionality in vitro. *Exp Toxicol Pathol* 2014; **66**: 187-194 [PMID: 24548687 DOI: 10.1016/j.etp.2014.01.003]

84 **Klinkhammer BM**, Kramann R, Mallau M, Makowska A, van Roeyen CR, Rong S, Buecher EB, Boor P, Kovacova K, Zok S, Denecke B, Stuettgen E, Otten S, Floege J, Kunter U. Mesenchymal stem cells from rats with chronic kidney disease exhibit premature senescence and loss of regenerative potential. *PLoS One* 2014; **9**: e92115 [PMID: 24667162 DOI: 10.1371/journal.pone.0092115]

**P-Reviewer:** Arash Z, Gharaee-Kermani M, Phinney DG

**S-Editor:** Qiu S **L-Editor: E-Editor:**

**Table 1 A summary of the results of isolating stem cells from the adult kidney**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |
| **Species** | **Isolation method** | **Stem cell markers** | **Location** | **Incorporation into kidney tubules** | **Ref.** |
|
|
| Rat | Label retaining |  | Proximal tubule | Yes | Maeshima *et al*[6] |
| Rat | Label retaining |  | Papilla | Yes | Oliver *et al*[8] |
|  |  |  |  |  |  |
| Rat | Side population | Sca-1, CD45 | Some were derived from bone marrow | No | Iwatani *et al*[10] |
|
| Mouse | Side population | Sca-1 | Interstitium | NE | Hishikawa *et al*[11] |
| Mouse | Side population | Sca-1 | Proximal tubule | Yes (Rare) | Challen *et al*[12] |
| Human | Marker | CD133 | Tubules | Yes | Bussolati *et al*[15] |
|  |  |  |  |  |  |
| Human | Marker | CD133, CD24 | Parietal epithelium in the Bowman's capsule | Yes | Sagrinati *et al*[16] |
|
| Mouse | Marker | Sca-1 | Papilla | Yes | Dekel *et al*[17] |
| Rat | Culture | Pax2, Oct4 | Proximal tubule | Yes | Gupta *et al*[18] |
| 　 | 　 | 　 | 　 | 　 | 　 |

NE: Not examined.

**Table 2 Effects of Bone marrow mesenchymal stem cells on renal tissue repair**

|  |  |  |  |
| --- | --- | --- | --- |
| **Origin of stem cells** | **Experimental model** | **Effects** | **Ref.** |
|  |  |  |  |
| Mouse | Glycerol-induced AKI | Differentiation into tubular epithelial cells | Herrera *et al*[22] |
|
| Mouse | Cisplatin-induced AKI | Differentiation into tubular epithelial cells | Morigi *et al*[23] |
|
| Human | Glomerulonephropathy induced by anti-mesangial cell serum | Differentiation into mesangial cells | Wong *et al*[30] |
|
| Rat | I/R injury | Recovery of renal functionNo transdifferentiation into tubules | Lange *et al*[24] |
|
| Human | Cisplatin-induced AKI | Recovery of renal functionImproved survivalNo transdifferentiation into tubules | Morigi *et al*[25] |
|
|
| Rat | Gentamicin-induced AKI | Recovery of renal functionConditioned medium and exosomes were effective | Reis *et al*[26] |
|
|
| Rat | Adriamycin-induced nephropathy | Reduced podocyte injuryIncreased VEGF production | Zoja *et al*[27] |
|
| Rat | Thy1.1 GN | Reduced mesangiolysisIncreased glomerular cell proliferationReduced proteinuriaProduction of VEGF and TGF- | Kunter *et al*[28] |
|
|
|
|
| Mouse | CKD (Deficiency in collagen type IV, -3 chain) | Reduced fibrosisProduction of VEGF and BMP-7 | Ninichuk *et al*[29] |
|
| Rat | 5/6 nephrectomy | Improved renal functionReduced fibrosisReduced expression of IL-6 and TNF- | Semedo *et al*[31] |
|
|
|
| Rat | Kidney allograft | Improved renal functionReduced fibrosisReduced expression of IL-6 | Franquesa *et al*[32] |
|
|

AKI: Acute kidney injury; I/R: Ischemia reperfusion; GN: Glomerulonephritis; CKD: Chronic kidney disease; VEGF: Vascular endothelial growth factor; TGF-: Transforming growth factor-; BMP-7: Bone morphogenetic protein-7; IL-6: Interleukin-6; TNF-: Tumor necrosis factor-.

**Table 3 Effects of adipose tissue-derived mesenchymal stem cells on renal tissue repair**

|  |  |  |  |
| --- | --- | --- | --- |
| Origin of stem cells | Experimental model | Effects | References |
|  |  |  |  |
| Rat | I/R injury | Recovery of renal functionReduction in oxidative stress | Chen *et al*[40] |
|
| Human | Cisplatin-induced AKI | Recovery of renal functionConditioned medium was effective | Kim *et al*[41] |
|
| Human | Folic acid-induced AKI | Recovery of renal functionHGF and VEGF production | Katsuno *et al*[42] |
|
| Rat | Anti-GBM disease | Reduced renal injury and proteinuriaConversion of macrophages to immunoregulatory cells | Furuhashi *et al*[43] |
|
|
|
| Swine | Renal artery stenosis | Recovery of renal functionImproved angiogenesisIncreased production of VEGF and bFGF | Eirin *et al*[44] |
|
|
|
| Swine | Renal artery stenosis | Recovery of renal functionImproved angiogenesisDecreased oxidative stress | Zhu *et al*[45] |
|
|
| Swine | Renal artery stenosis | Recovery of renal functionImproved angiogenesisIncreased production of VEGF | Ebrahimi *et al*[46] |
|
|
| Mouse | Renal fibrosis (Unilateral clamping of the renal pedicle) | Recovery of renal functionReduced fibrosisDecreased expression of IL6 and TNF | Donizetti-Oliveira *et al*[47] |
|
|
|

I/R: Ischemia reperfusion; AKI: Acute kidney injury; GBM: Glomerular basement membrane; HGF: Hepatocyte growth factor; VEGF: Vascular endothelial growth factor; bFGF: Basic fibroblast growth factor; IL-6: Interleukin-6; TNF-: Tumor necrosis factor-.